Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole
Status:
Completed
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
This proposal aims to use well-validated methodologies such as dual energy x-ray
absorptiometry (DEXA), frequently sampled oral glucose tolerance tests (fsOGTTs), and
hyperinsulinemic euglycemic clamps to characterize the metabolic effects of 12 weeks of
aripiprazole treatment following chronic pretreatment with olanzapine, quetiapine,
risperidone or ziprasidone.
We hypothesize that switching to aripiprazole treatment will induce improvements in total
body adiposity, inflammation (e.g., high sensitivity C-reactive protein [hsCRP]), glucose
metabolism (e.g., insulin sensitivity) and lipid metabolism (e.g., fasting plasma
triglyceride), in comparison to chronic pretreatment with olanzapine, risperidone and
quetiapine.